{
  "asset": {
    "name": "KT-621",
    "company": "Kymera Therapeutics",
    "ticker": "KYMR",
    "target": "STAT6",
    "target_full_name": "Signal Transducer and Activator of Transcription 6",
    "mechanism": "STAT6 degrader (targeted protein degradation)",
    "modality": "Oral small molecule degrader",
    "pathway": "IL-4/IL-13 signaling",
    "competitor_reference": "Dupilumab (Dupixent) - $13B+ annual sales"
  },
  "clinical_development": {
    "current_stage": "Phase 2b",
    "indications_in_development": [
      "Atopic Dermatitis",
      "Asthma",
      "COPD",
      "Eosinophilic Esophagitis (EoE)",
      "Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)",
      "Chronic Spontaneous Urticaria (CSU)",
      "Prurigo Nodularis (PN)",
      "Bullous Pemphigoid (BP)"
    ],
    "market_opportunity": ">140M patients; only ~1% on advanced systemic therapies; >$20B market projected by 2030"
  },
  "trials": [
    {
      "name": "KT-621 Phase 1 Healthy Volunteer Study (SAD/MAD)",
      "phase": "Phase 1",
      "status": "Completed",
      "indication": "Healthy Volunteers",
      "design": "Single and multiple ascending dose, randomized, placebo-controlled",
      "arms": [
        {
          "name": "Placebo",
          "n": 18,
          "duration": "14 days"
        },
        {
          "name": "KT-621 1.5mg QD",
          "dose": "1.5mg",
          "frequency": "QD",
          "n": 9
        },
        {
          "name": "KT-621 12.5mg QD",
          "dose": "12.5mg",
          "frequency": "QD",
          "n": 7
        },
        {
          "name": "KT-621 25mg QD",
          "dose": "25mg",
          "frequency": "QD",
          "n": 9
        },
        {
          "name": "KT-621 50mg QD",
          "dose": "50mg",
          "frequency": "QD",
          "n": 9
        },
        {
          "name": "KT-621 100mg QD",
          "dose": "100mg",
          "frequency": "QD",
          "n": 9
        },
        {
          "name": "KT-621 200mg QD",
          "dose": "200mg",
          "frequency": "QD",
          "n": 9
        }
      ],
      "endpoints": [
        {
          "name": "STAT6 degradation - Blood",
          "category": "biomarker",
          "result": ">90% at doses \u226525mg QD",
          "timepoint": "Day 14"
        },
        {
          "name": "STAT6 degradation - Skin",
          "category": "biomarker",
          "result": ">90% at doses \u226525mg QD",
          "timepoint": "Day 14"
        },
        {
          "name": "Serum TARC reduction",
          "category": "biomarker",
          "result": "-20 to -40%",
          "dose_group": "50-200mg QD",
          "timepoint": "Day 14"
        },
        {
          "name": "Serum Eotaxin-3 reduction",
          "category": "biomarker",
          "result": "-40 to -70%",
          "dose_group": "100-200mg QD",
          "timepoint": "Day 14"
        }
      ],
      "safety": "Well-tolerated; safety profile undifferentiated from placebo; no SAEs; no dose-dependent TEAEs"
    },
    {
      "name": "BroADen Phase 1b in Atopic Dermatitis",
      "phase": "Phase 1b",
      "status": "Completed",
      "indication": "Moderate-to-severe Atopic Dermatitis",
      "design": "Single arm, open label",
      "population": "Adult moderate-to-severe AD patients (EASI\u226516, vIGA-AD\u22653, PPNRS\u22654, BSA\u226510%)",
      "arms": [
        {
          "name": "KT-621 100mg QD",
          "dose": "100mg",
          "frequency": "QD",
          "n": 10,
          "duration": "28 days"
        },
        {
          "name": "KT-621 200mg QD",
          "dose": "200mg",
          "frequency": "QD",
          "n": 12,
          "duration": "28 days"
        }
      ],
      "endpoints": [
        {
          "name": "STAT6 degradation - Blood",
          "category": "biomarker",
          "result": "98% median",
          "timepoint": "Day 29"
        },
        {
          "name": "STAT6 degradation - Skin",
          "category": "biomarker",
          "result": "94%",
          "timepoint": "Day 29"
        },
        {
          "name": "EASI % Change",
          "category": "primary",
          "result": "-63%",
          "dose_group": "Overall (n=22)",
          "timepoint": "Day 29"
        },
        {
          "name": "EASI-50",
          "category": "secondary",
          "result": "76% achieved",
          "timepoint": "Day 29"
        },
        {
          "name": "EASI-75",
          "category": "secondary",
          "result": "29% achieved",
          "timepoint": "Day 29"
        },
        {
          "name": "vIGA-AD 0/1",
          "category": "secondary",
          "result": "19% achieved",
          "timepoint": "Day 29"
        },
        {
          "name": "SCORAD % Change",
          "category": "secondary",
          "result": "-48%",
          "timepoint": "Day 29"
        },
        {
          "name": "Peak Pruritus NRS % Change",
          "category": "secondary",
          "result": "-40%",
          "timepoint": "Day 29"
        },
        {
          "name": "TARC reduction",
          "category": "biomarker",
          "result": "-74%",
          "timepoint": "Day 29"
        },
        {
          "name": "Eotaxin-3 reduction",
          "category": "biomarker",
          "result": "-73%",
          "timepoint": "Day 29"
        },
        {
          "name": "IL-31 reduction",
          "category": "biomarker",
          "result": "-54%",
          "timepoint": "Day 29"
        },
        {
          "name": "FeNO reduction (comorbid asthma, n=4)",
          "category": "biomarker",
          "result": "-56%",
          "timepoint": "Day 29"
        },
        {
          "name": "ACQ-5 responders (comorbid asthma)",
          "category": "secondary",
          "result": "100% (4/4)",
          "timepoint": "Day 29"
        }
      ],
      "safety": "Well-tolerated; no SAEs; no severe AEs; no dose-dependent TEAEs; no conjunctivitis",
      "vs_dupilumab": "Results in line with or numerically exceeded published Dupilumab data at Week 4"
    },
    {
      "name": "BROADEN2 Phase 2b in Atopic Dermatitis",
      "phase": "Phase 2b",
      "status": "Ongoing",
      "indication": "Moderate-to-severe Atopic Dermatitis",
      "design": "Randomized, double-blind, placebo-controlled, dose-ranging",
      "population": "Adult & adolescent (12-75) moderate-to-severe AD",
      "n_target": 200,
      "arms": [
        {
          "name": "Placebo"
        },
        {
          "name": "KT-621 Dose 1"
        },
        {
          "name": "KT-621 Dose 2"
        },
        {
          "name": "KT-621 Dose 3"
        }
      ],
      "primary_endpoint": "Percent change from baseline in EASI score at Week 16",
      "secondary_endpoints": [
        "EASI-50",
        "EASI-75",
        "vIGA-AD 0/1",
        "Peak Pruritus NRS \u22654-point improvement"
      ],
      "duration": "16 weeks + 52-week open label extension",
      "data_expected": "Mid-2027"
    },
    {
      "name": "BREADTH Phase 2b in Asthma",
      "phase": "Phase 2b",
      "status": "Initiated January 2026",
      "indication": "Moderate-to-severe Eosinophilic Asthma",
      "design": "Randomized, double-blind, placebo-controlled, dose-ranging",
      "population": "Adult moderate-to-severe eosinophilic asthma (EOS\u2265300, FeNO\u226525ppb, FEV1 40-80%)",
      "n_target": 264,
      "arms": [
        {
          "name": "Placebo"
        },
        {
          "name": "KT-621 Dose 1"
        },
        {
          "name": "KT-621 Dose 2"
        },
        {
          "name": "KT-621 Dose 3"
        }
      ],
      "primary_endpoint": "Percent change from baseline in pre-bronchodilator FEV1 at Week 12",
      "secondary_endpoints": [
        "ACQ-5 change",
        "AQLQ change"
      ],
      "duration": "12 weeks",
      "data_expected": "Late-2027"
    }
  ],
  "graph_analyses": {
    "phase1_biomarker": {
      "title": "STAT6 Degradation in Blood and Skin",
      "key_findings": [
        "Clear sigmoid dose-response: minimal at 1.5mg, steep 12.5-25mg, plateau \u226525mg",
        ">90% STAT6 degradation in both blood AND skin at doses \u226525mg",
        "Skin penetration confirmed - critical for dermatological indications",
        "TARC/Eotaxin-3 reductions suggest on-target Type 2 pathway blockade"
      ],
      "clinical_significance": "Deep target tissue engagement at well-tolerated oral doses supports Dupixent-like potential"
    },
    "phase1b_efficacy": {
      "title": "EASI and SCORAD Response Over Time",
      "key_findings": [
        "Rapid onset: significant EASI improvement by Day 8",
        "Progressive improvement without plateau at Day 29",
        "63% EASI reduction comparable to Dupixent at similar timepoint",
        "100mg and 200mg show similar efficacy - 100mg likely optimal dose",
        "Strong itch reduction (PPNRS -40%) indicates symptomatic relief"
      ],
      "clinical_significance": "Open-label data directionally supports Dupixent-like efficacy; Phase 2b will confirm with placebo control"
    }
  },
  "investment_thesis": [
    "First oral STAT6 degrader - potential to replace/complement Dupixent ($13B+ blockbuster)",
    "Phase 1b AD: 63% EASI reduction at Day 29 matches/exceeds Dupixent at Week 4",
    "Oral convenience advantage over Dupixent (injection every 2 weeks)",
    "Broad indication potential: AD, asthma, COPD, EoE, CRSwNP, CSU, PN, BP",
    "Market opportunity: >140M patients, <1% on advanced therapy, >$20B by 2030",
    "Deep target engagement: >90% STAT6 degradation in blood AND skin",
    "Favorable safety: no conjunctivitis (common Dupixent AE), no SAEs"
  ],
  "key_risks": [
    "Phase 1b was open-label - need placebo-controlled Phase 2b to confirm efficacy",
    "Only 29 days treatment - need 16-week data for proper Dupixent comparison",
    "Small sample sizes (n=22 in Phase 1b)",
    "Competitive landscape: Dupixent entrenched, other IL-4/IL-13 drugs in development",
    "Degrader class relatively new - long-term safety profile still being established"
  ],
  "upcoming_catalysts": [
    {
      "event": "BROADEN2 Phase 2b AD data",
      "timing": "Mid-2027"
    },
    {
      "event": "BREADTH Phase 2b Asthma data",
      "timing": "Late-2027"
    },
    {
      "event": "Phase 3 dose selection",
      "timing": "2027"
    }
  ]
}